GGrantIndex
← Search

Data Bank & BioRepository

$165,573P30FY2012CANIH

Roswell Park Cancer Institute Corp, Buffalo NY

Investigators

Linked publications, trials & patents

Trial NCT07082270Trial NCT06202066Trial NCT05589844Trial NCT05338905Trial NCT05292521Trial NCT05231122Trial NCT04607291Trial NCT04533542Trial NCT04530812Trial NCT04526587Trial NCT04379518Trial NCT04358315Trial NCT04348747Trial NCT04298606Trial NCT04290962Trial NCT04269213Trial NCT04231539Trial NCT04207190Trial NCT04119830Trial NCT04110249Trial NCT04109924Trial NCT04093323Trial NCT04081389Trial NCT04073745Trial NCT04068649Trial NCT04067830Trial NCT04060446Trial NCT04032418Trial NCT04000581Trial NCT03965234Trial NCT03935347Trial NCT03899987Trial NCT03897270Trial NCT03895918Trial NCT03881735Trial NCT03880422Trial NCT03879694Trial NCT03865472Trial NCT03851081Trial NCT03793907Trial NCT03789877Trial NCT03751449Trial NCT03751436Trial NCT03736720Trial NCT03735589Trial NCT03735095Trial NCT03727789Trial NCT03727061Trial NCT03709550Trial NCT03691376Trial NCT03688945Trial NCT03685695Trial NCT03683147Trial NCT03680235Trial NCT03679585Trial NCT03679559Trial NCT03678350Trial NCT03630601Trial NCT03574792Trial NCT03457142Trial NCT03403634Trial NCT03384836Trial NCT03358719Trial NCT03348748Trial NCT03333486Trial NCT03297489Trial NCT03211416Trial NCT03206047Trial NCT03192397Trial NCT03090412Trial NCT03017131Trial NCT03011736Trial NCT02965976Trial NCT02955290Trial NCT02953457Trial NCT02947386Trial NCT02877641Trial NCT02857374Trial NCT02853318Trial NCT02833506Trial NCT02713373Trial NCT02650986Trial NCT02575885Trial NCT02575508Trial NCT02531906Trial NCT02474095Trial NCT02455557Trial NCT02452463Trial NCT02414724Trial NCT02399215Trial NCT02393755Trial NCT02334865Trial NCT02287727Trial NCT02227940Trial NCT02170389Trial NCT02166905Trial NCT02159950Trial NCT02119728Trial NCT02100254Trial NCT02072486

Abstract

The usefulness of basic science advances to cancer prevention, diagnosis and treatment outcomes may be limited if it is not linked to epidemiological as well as clinical characteristics of study participants. The goal of the Data Bank and BioRepository (DBBR) Resource is to meet the scientific needs of CCSG Program members for studies of cancer etiology, detection, treatment and prognosis, by providing detailed data on participants, including exposure, medical, dietary and lifestyle histories, matched with biologic specimens. This new Resource was established with the Institute and CCSG Developmental funds. It is anticipated that the number of members from all CCSG programs using the Resource will increase as its holdings expand. Samples include aliquots of plasma, serum, red blood cells and DNA extracts that are collected, processed and stored in a rigorous manner and linked with clinical patient information. Cancer patients, as well as those at high risk of cancer, are consented by DBBR staff to provide a blood specimen to be used for future research, to complete an in-depth epidemiological questionnaire and to allow linkage with data from their medical records as well as any results from studies performed using their archived tissue. Cancer-free family members, friends and visitors of patients also are invited to participate to serve as 'controls' and are consented in a similar fashion. Standardized procedures are in place for eligible participant identification, consenting and collection of biospecimens, and enrollment is conducted through clinics for most cancer sites. To ensure quality, specimens are immediately processed, stored in 0.5ml aliquots and stored in liquid nitrogen, to maintain collection-to-freeze time standards to minimize sample degradation. Detailed annotation and tracking procedures are in place. Cell viability analyses are conducted in collaboration with the Flow and Image Cytometry Resource. DNA extraction is performed by the Microarray and Genomics Resource. Quality of clinical, epidemiological, and specimen tracking and inventory is managed through highly relational, password-protected databases and customized software. Samples and data are available through a chargeback mechanism to CCSG Program members and include those from patients diagnosed with breast, lung, GYN, GU, Gl, head and neck, melanoma, soft tissue sarcoma, lymphoma, neurological cancers as well as bone marrow transplant patients. This Resource is unique for translational research because it provides high-quality epidemiological data linked to rigorously processed biospecimens that are characterized by pathological and clinical information; thereby, actively facilitating studies of cancer risk, progression and outcome in an environment that ensures confidentiality. The Resource is used by all six CCSG Programs and 99% of users are CCSG members. $77,818 in CCSG support is requested, representing 18% of the total operating budget.

View original record on NIH RePORTER →
Data Bank & BioRepository · GrantIndex